Rottendorf Pharmaceuticals has recently signed three formulation development projects and two commercial transfer projects with several top five Pharma/Biopharma companies. Additional details were not disclosed.

“The new projects signed in the last quarter reflect the industry’s positive response to our business model and our commitment to Total Process Ownership (TPO),” said Rottendorf Pharmaceuticals chief executive officer, Gordon Haines. “TPO relies on open communication and exchange of ideas with our pharma partners and draws on 85 years of formulation development and manufacturing experience to recommend process optimizations to ultimately produce a better end product.”

Under TPO, Rottendorf assumes a high degree of process responsibility and ownership aimed at reducing management oversight for the client; reduced complexity and supply chain improvements.

Mr. Haines added, “We are owned by a charitable foundation, which allows us to focus more on long-term success of our business and the goals of our customers, rather than needing to satisfy shareholders on a quarter-by-quarter basis.”